Duloxetine Metabolism and Fibromyalgia
University of Utah
100 participants
May 1, 2025
OBSERVATIONAL
Conditions
Summary
People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult. The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine. The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.
Eligibility
Inclusion Criteria3
- Adults 18+
- Meeting diagnostic criteria for Fibromyalgia
- Patients taking Duloxetine 60 mg/day for at least 8 weeks
Exclusion Criteria4
- Pregnant patients per verbal confirmation
- Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.
- Patients requiring an interpreter to communicate
- Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In a cohort of patients treated with duloxetine for fibromyalgia, participants vitals signs (blood pressure, heart rate, oxygen saturation level, temperature) will be taken as well as height and weight. Participants will fill out a questionnaire regarding their fibromyalgia diagnosis and symptoms. Lastly, participants will complete two sets of blood samples. One blood sample will evaluate genetic variants for duloxetine metabolizing capacity. The other sample will be used to analyze the level of concentration of duloxetine.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06866444